Key statistics
On Thursday, ProQR Therapeutics NV (PRQR:NAQ) closed at 1.78, 60.36% above the 52 week low of 1.11 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.80 |
---|---|
High | 1.82 |
Low | 1.76 |
Bid | 1.71 |
Offer | 2.28 |
Previous close | 1.80 |
Average volume | 74.30k |
---|---|
Shares outstanding | 81.68m |
Free float | 66.33m |
P/E (TTM) | -- |
Market cap | 145.39m USD |
EPS (TTM) | -0.2956 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
- ProQR Announces Second Quarter 2024 Operating and Financial Results
- ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
- ProQR Announces First Quarter 2024 Operating and Financial Results
- ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
More ▼